Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Scancell Holdings Plc (SCLP.LN)

Scancell Holdings Plc (SCLP.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Scancell Holdings Plc Sanders Road Unit 202, Bellhouse Building Oxford OX4 4GD GBR

https://www.scancell.co.uk P: 186-558-2066

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.

Key Statistics

Overview:

Market Capitalization, $K 121,420
Shares Outstanding, K 1,037,781
% of Insider Shareholders 15.45%
% of Institutional Shareholders 1.52%

Financials:

Annual Sales, $ 4,711 K
Annual Net Income, $ -12,272 K

Growth:

1-Year Return 29.43%
3-Year Return -54.14%
5-Year Return -17.12%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.01
Dividend Payout Ratio 0.00%
Most Recent Split 10-1 on 07/26/11

SCLP.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % N/A
Return-on-Assets % -52.60%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales 24.10
Price/Book N/A
Book Value/Share 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar